Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nasal congestion, Oropharyngeal discomfort, Oropharyngeal pain, Pain
Clinical narrative: patient test POSITIVE for COVID-19; patient test POSITIVE for COVID-19; fatigue; loss of taste; nasal congestion; temperature was increasing from 98.5F to 102.9F; body aches; headache; dry cough; sore throat.; feel sand in the throat; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from product quality group. The reporter is the patient.  A 29 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 29Oct2021 (Lot number: FG3527) at the age of 29 years as dose 3 (booster), single, intramuscular, administered in arm left, administration date 23Apr2021 (Lot number: EW0172) as dose 2, single and intramuscular, administered in arm left, administration date 02Apr2021 (Lot number: EW0150) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Penicillin" (unspecified if ongoing); "obesity" (unspecified if ongoing), notes: (bariatric patient); "COVID-19" (unspecified if ongoing), notes: if covid prior vaccination Yes; "bariatric patient" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Ibuprofen, reaction(s): "known allergies:Ibuprofen", notes: Ibuprofen. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 02Feb2022, outcome "recovering" and all described as "patient test POSITIVE for COVID-19"; OROPHARYNGEAL DISCOMFORT (non-serious) with onset 31Jan2022 16:30, outcome "recovering", described as "feel sand in the throat"; PYREXIA (non-serious) with onset 01Feb2022, outcome "recovering", described as "temperature was increasing from 98.5F to 102.9F"; PAIN (non-serious) with onset 01Feb2022, outcome "recovering", described as "body aches"; HEADACHE (non-serious) with onset 01Feb2022, outcome "recovering", described as "headache"; COUGH (non-serious) with onset 01Feb2022, outcome "recovering", described as "dry cough"; OROPHARYNGEAL PAIN (non-serious) with onset 01Feb2022, outcome "recovering", described as "sore throat."; FATIGUE (non-serious) with onset 02Feb2022, outcome "recovering", described as "fatigue"; AGEUSIA (non-serious) with onset 02Feb2022, outcome "recovering", described as "loss of taste"; NASAL CONGESTION (non-serious) with onset 02Feb2022, outcome "recovering", described as "nasal congestion". The patient underwent the following laboratory tests and procedures: body temperature: (01Feb2022) 102.9f, notes: Increasing from 98.5F to 102.9F; covid-19: (03Feb2022) positive; sars-cov-2 test: (02Feb2022) positive, notes: Nasal Swab. Therapeutic measures were taken as a result of vaccination failure, covid-19, oropharyngeal discomfort, pyrexia, pain, headache, cough, oropharyngeal pain, fatigue, ageusia, nasal congestion.  Clinical course: On 31Jan2022 evening patient started to feel sand in the throat. On 01Feb2022 in the morning patient had 1 Benadryl for the feeling sand on the throat. On the same date in the afternoon patient temperature was increasing from 98.5F to 102.9F, she started to feel body aches, headache, dry cough and sore throat. Thus patient scheduled a COVID test for 02Feb2022. On 01Feb2022 patient had Tylenol gel for fever 1 capsule each 6 hours and Robitussin for cough 20 mL each 4 hours. On 02Feb2022 patient did the COVID test. On the same day patient still had fever, body aches, sore throat, and starts to feel fatigue, loss of taste and nasal congestion. On 03Feb2022 patient test Positive for COVID-19. On 03Feb2022 patient does not have more fever, and the body aches was getting better. Patient still have with mild fatigue and headache. Patient still presenting the other events. Patient had covid prior vaccination and tested covid post vaccination. No other vaccine in four weeks. No other medications in two weeks.  No follow-up attempts are possible. No further information is expected; Sender's Comments: Based on available information, a possible contributory role of BNT162B2 vaccine cannot be excluded for the reported events of COVID-19 and Vaccination failure.